Lucigen Corporation is pleased to announce that it has recently been awarded three new grants to fund additional research and development.

The National Institutes of Health has awarded Lucigen $1,764,732 in Small Business Innovation Research grants to be used over two years to develop research tools and diagnostic assays with potential to improve human health. The grants include funding for: 1) development of a simple, sensitive, all-in-one point of care virus-detection system (Phase I award of $400,000), 2) advancement of cloning methods with the goal of identifying novel antibiotics for future clinical development (Phase I award of $164,732), and 3) enhancement of a system for expressing genes which are toxic or unstable in currently available systems (Phase II award of $1,200,000). These three grants will be used to support researchers and enable Lucigen to leverage their expertise in the fields of Genomics and Proteomics.

“We are pleased to receive this additional funding to support our research. These grants will provide Lucigen with the resources we need to rapidly advance our work on new products to support basic and applied medical research, as well as clinical diagnostics” according to David Mead, Ph.D., founder and CEO.